More ample international deployment
International presence is a major component of Genopole’s growth strategy. Building intercluster alliances increases the impact and reach of actions to support innovation. Being present for biotech events wherever they may be in the world seats Genopole’s renown and enables benchmarking against best practices and the prospection of companies potentially interested in joining the biocluster.
Although the pandemic hampered in-person possibilities, a number of European and extra-European events were held.
BIO, the world’s top international biotech convention, was held virtually in June. For the event, Genopole partnered with Business France, Choose Paris Region, Medicen and others to promote the advantages of the Île-de-France Region. The videoconference united 21 companies sharing their aspirations for development in France. BIO strengthened Genopole’s ties to the North Carolinian (USA) research cluster Triangle Park, the Japanese cluster Kawasaki and the Belgian cluster BioWin.
To increase the biocluster’s visibility in the United States, Genopole participated in a meeting organized by the Ohio Chapter of the French-American Chamber of Commerce, notably on the subject of the health and biotech sectors. The event was an opportunity to attract American companies to the biocluster and ease the arrival of Genopole companies in the US.
In Europe
Held in Munich, the Old Continent’s BIO International twin, BIO-Europe Spring, was a privileged opportunity to meet with new (CataloniaBio (Spain)) and already-known (BioWin (Wallonia, Belgium), BioM (Munich Germany), etc.) clusters and participate in close to 30 meetings with several pharmaceutical companies such as BJT Pharma and key account companies like Seppic, a specialist in cosmetics, dietary supplements and pharmaceutical ingredients.
There too, Genopole, an event "Gold Sponsor" with Choose Paris Region and Medicen, promoted the assets of the Île-de-France Region in health innovation and especially the biomanufacturing sector.
Year 2021 also brought new partnerships with European clusters. The Eastern European nations were given priority because of their strong potential in computational genomics and innovative biotherapies, both strategic sectors for Genopole. Partnerships were created with Lithuanian (Lithuanian Biotechnology Association), Estonian (Tartù Biocluster/University), Slovenian (Technology Park Ljubljana), Danish (Medicon) and German (Biocon Valley) clusters, with which Genopole was able to submit the European projects URINBB and Braintech.
The biocluster also reinforced its ties to the ALISEI (Advanced Life Science in Italy) network, created during the September Meet in Italy event (more than 300 participants from the field of health biotechnologies) to encourage interactions between multidisciplinary research, pharmaceutical industries and public health organisms in Italy.